A Phase 2 clinical trial involving goserelin changed status as of August 28, 2026. The study, registered as NCT04325828 and titled "A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma," is now listed as active, not recruiting.
The trial evaluates apalutamide combined with a GnRH agonist, goserelin, in participants with androgen receptor positive salivary gland carcinoma. It is registered as a Phase 2 study on ClinicalTrials.gov.
The active, not recruiting status indicates that enrollment has closed but participants may still be receiving treatment or being followed according to the study protocol. No results or outcome data have been reported as part of this update.
This status update reflects only the trial's operational stage, not any efficacy or safety findings. Interested readers should consult the ClinicalTrials.gov listing for full protocol details, including eligibility criteria and study design specifics.
For more background on this compound, see the goserelin overview page.